Photo of Benedikt Westphalen taken from LinkedIn
May 3, 2024, 11:26
Ben Westphalen: The 2nd tumour agnostic, biomarker-driven approval in the EU
Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, shared a post on X:
“Big news for European cancer patients.
Selpercatinib has been approved by EU Medicines Agency for advanced RET fusion positive solid tumours This marks the 2nd tumour agnostic, biomarker-driven approval in the EU. ”
Read further.
Source: Ben Westphalen/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59
Nov 13, 2024, 10:54